secwatch.observer — SEC 8-K summary
======================================

Issuer:     CONMED Corp (CNMD)
CIK:        0000816956
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001174947-23-000151
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CONMED reports Q4 sales down 8.4%, adj. EPS down 60.7% on warehouse software disruption
--------------------------------------------------------------------------------

- Q4 sales $250.9M (-8.4% YoY); GAAP EPS $0.86 vs $0.75 YoY; adjusted EPS $0.42 vs $1.07.
- Full-year sales $1,045.5M (+3.4%); GAAP net loss per share $2.68; adjusted EPS $2.65 (-17.4%).
- Q4 disruptions from new warehouse management system; management cites daily shipping now at or above historical rates.
- 2023 guidance: revenue $1.17B-$1.22B, adjusted EPS $3.20-$3.45, with FX headwind of $0.20-$0.25 per share.
- Completed acquisitions of In2Bones (June 2022) and Biorez (Aug 2022), contributing ~240bps to full-year growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/816956/000117494723000151/0001174947-23-000151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/816956/000117494723000151/form8k-29345_cnmd.htm
  HTML page:      https://secwatch.observer/filing/0001174947-23-000151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer